Cart123 Cells
Childhood Acute Myeloid Leukemia
Explore 46 assets in Childhood Acute Myeloid Leukemia →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
University of Pennsylvania
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04678336CT.gov CD123 Redirected T Cells for AML in Pediatric Subjects | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cart123 Cells (this asset) | University of Pennsylvania | P1 | CC · 43 |
| Etoposide | Joanna Yi | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Methotrexate | Children's Oncology Group | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P3 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Romidepsin | Washington University School of Medicine | P3 | BB |
| Busulfanum | Washington University School of Medicine | P3 | BB |
+42 more in the Childhood Acute Myeloid Leukemia cohort
Other indications for Cart123 Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cart123 Cells in Childhood Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cart123-cells-childhood-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →